This webinar includes a panel discussion of key topics in the field of cancer immunotherapy, including new and emerging methods, recent publications, and future directions. The links between preclinical research, in vivo studies, and biomarkers are explored, as well as the unique advantages of Crown Bioscience and their service offerings.

Key Topics Include:

  • How our understanding of the cancer immunity cycle impacts cancer immunotherapy development
  • Which new in vitro technologies provide more physiological and translatable drug responses
  • Why HCI is providing deeper insights into drug responses
  • What novel solutions are on the horizon to overcome the challenges of immunotherapeutic development

Resources

Presenters

Director of Immuno-Oncology
Crown Bioscience

Trained as an immunologist, Gera Goverse has used novel technologies to study the role of different environmental factors on both the local and systemic immune system to suppress their responses in inflammatory disorders and in the field of immuno-oncology. Since joining the team at Crown Bioscience, Gera has executed the design of many successful immuno-oncology projects to help national and international customers discover the full potential of their compounds. Gera is motivated by studying the complex mechanisms of the regulation of the immune system, exploring tumor-cell interactions and refining ways to stimulate the immune responses towards the killing of the tumor.

Vice President
Research & Innovation
Crown Bioscience

As a pharmacologist with over 15 years of experience in the CRO/biotech industry and expertise in preclinical development of oncology drugs and vaccines, Ludovic is passionate about helping customers accelerate their early-stage drug development.

Senior Vice President of In Vitro, Head of Crown Bioscience Netherlands
Crown Bioscience

Leo Price leads Crown Bioscience’s in vitro services in Europe and the US and the Crown Bioscience sites in The Netherlands, Leiden and Utrecht. He joined Crown Bioscience in 2021 from OcellO, following Crown Bioscience’s acquisition of the company. Dr Price was the founder of OcellO, a leading provider of high content screening services, using organoids and other advanced 3D cell culture models, and served as their CEO and CSO for ten years.

Production Partner

Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing discovery, preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases.

Additional Content From Crown Bioscience

Additional Content From Scientist.com

Related Content